Table S10. Predictive effect of the copy number of genomic regions. Multivariate results in optimal quality samples only.
| Chr | Region ID | CNA frequency | Disease-free survival | Overall survival | Lung-cancer specific survival | Mb | cytoBands | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Losses | Gains | HR for loss* (95% CI) | HR for gain** (95% CI) | P | HR for loss* (95% CI) | HR for gain** (95% CI) | P | HR for loss* (95% CI) | HR for gain** (95% CI) | P | |||||||
| 14 | 319 | 10.8% | 11.4% | 0.25 (0.10–0.62) | 4.0 (1.6–10) | 0.003 | 1.0E−1 | q32.33 | |||||||||
| 18 | 368 | 12.1% | 6.6% | 2.6 (1.1–6.1) | 0.39 (0.16–0.91) | 0.029 | 1.0E−3 | q12.1 | |||||||||
| 20 | 407 | 1.3% | 18.4% | 0.19 (0.05– 0.77) | 5.2 (1.3–21) | 0.020 | 5.0E−2 | q11.21 | |||||||||
Results from a model adjuster by treatment arm, patient age, sex, performance status (PS), histology, T, and N stage. *, hazard ratio for a 2-fold lower copy number; **, hazard ratio for a 2-fold higher copy number.